4.7 Article

Microbial Interactions in the Cystic Fibrosis Airway

Journal

JOURNAL OF CLINICAL MICROBIOLOGY
Volume 56, Issue 8, Pages -

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/JCM.00354-18

Keywords

Burkholderia; Pseudomonas aeruginosa; Staphylococcus aureus; airway infections; cystic fibrosis; logistic regression; microbial ecology

Categories

Funding

  1. Cystic Fibrosis Foundation, Bethesda, MD, USA [LIOU14P0]
  2. Ben B. and Iris M. Margolis Family Foundation of Utah award
  3. Claudia Ruth Goodrich Stevens Endowment Fund
  4. National Heart, Lung, and Blood Institute [T32HL105321, R01HL125520]
  5. Medical Research Council Fellowship [MR/M014827/1]
  6. Army Research Office (ARO) [W911NF-15-1-0400]
  7. National Science Foundation Division of Mathematical Sciences [RTG: NSF-DMS 1148230]
  8. NIH Cancer Systems Biology Consortium [U54 CA209978]
  9. Cystic Fibrosis Foundation
  10. University of Utah [CC132-16AD]
  11. Gilead Sciences
  12. Nivalis Therapeutics, Inc.
  13. Novartis
  14. Proteostasis Therapeutics, Inc.
  15. Savara Pharmaceuticals
  16. Vertex Pharmaceuticals
  17. MRC [MR/M014827/1] Funding Source: UKRI

Ask authors/readers for more resources

Interactions in the airway ecology of cystic fibrosis may alter organism persistence and clinical outcomes. Better understanding of such interactions could guide clinical decisions. We used generalized estimating equations to fit logistic regression models to longitudinal 2-year patient cohorts in the Cystic Fibrosis Foundation Patient Registry, 2003 to 2011, in order to study associations between the airway organisms present in each calendar year and their presence in the subsequent year. Models were adjusted for clinical characteristics and multiple observations per patient. Adjusted models were tested for sensitivity to cystic fibrosis-specific treatments. The study included 28,042 patients aged 6 years and older from 257 accredited U.S. care centers and affiliates. These patients had produced sputum specimens for at least two consecutive years that were cultured for methicillin-sensitive Staphylococcus aureus, methicillin-resistant S. aureus, Pseudomonas aeruginosa, Burkholderia cepacia complex, Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and Candida and Aspergillus species. We analyzed 99.8% of 538,458 sputum cultures from the patients during the study period. Methicillin-sensitive S. aureus was negatively associated with subsequent P. aeruginosa. P. aeruginosa was negatively associated with subsequent B. cepacia complex, A. xylosoxidans, and S. maltophilia. B. cepacia complex was negatively associated with the future presence of all bacteria studied, as well as with that of Aspergillus species. P. aeruginosa, B. cepacia complex, and S. maltophilia were each reciprocally and positively associated with Aspergillus species. Independently of patient characteristics, the organisms studied interact and alter the outcomes of treatment decisions, sometimes in unexpected ways. By inhibiting P. aeruginosa, methicillin-sensitive S. aureus may delay lung disease progression. P. aeruginosa and B. cepacia complex may inhibit other organisms by decreasing airway biodiversity, potentially worsening lung disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available